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Relationship between serum B12
concentrations and mortality: experience in
NHANES
Bruce H. R. Wolffenbuttel1*, M. Rebecca Heiner-Fokkema2, Ralph Green3 and Rijk O. B. Gans4
Abstract
Background: There is conflicting evidence in the literature on the association between (elevated) serum B12
concentrations and subsequent disease or mortality. We evaluated in the NHANES general population the association
of serum B12 concentrations as well as vitamin B12 supplement intake with all-cause, cardiovascular, and cancer-
related mortality, while taking into account demographic and lifestyle factors and significant other diseases which are
known to be associated with poorer outcome.
Methods: The main outcomes of our study were all-cause mortality, cardiovascular mortality, and cancer-related
mortality. Mortality status and cause of death were determined by NHANES-linked National Death Index public access
files through December 31, 2015. The association of serum B12 concentrations and vitamin B12 supplement intake
with mortality was assessed with Cox proportional hazard (PH) models, with adjustment for a number of relevant
demographic and lifestyle factors and comorbidity.
Results: The final study population of 24,262 participants had a mean age of 48 (SD 19) years; 50.1% were males. The
median follow-up duration was 109months (range 1–201months). On the census day of December 31, 2015, 3023
participants were determined as deceased (12.5%). The fully adjusted Cox PH model indicated that low serum B12
concentrations < 140 pmol/l were associated with a small increase in all-cause (hazard ratio, HR 1.39, 95% CI 1.08–1.78,
p = 0.011) and cardiovascular (HR 1.64, 95% CI 1.08–2.47, p = 0.020) mortality. Similarly, high serum B12 concentrations
> 700 pmol/l were associated with an increase in cardiovascular mortality only (HR 1.45, 95% CI 1.01–2.06, p = 0.042).
Participants with a diagnosis of hypertension, dyslipidemia, CVD, and cancer more frequently used vitamin B12-
containing supplements than those without these diagnoses. We could not demonstrate an association between
vitamin B12 supplement intake and mortality, when adjusted for comorbidity.
Conclusions: In the general population of NHANES, low serum B12 concentrations were associated with a moderate
increase in all-cause mortality. There was a small but significant increase in cardiovascular mortality in the groups with
low or high serum B12. High intake of vitamin B12 in the form of supplements was not associated with any adverse
effect on mortality and therefore can be regarded as safe.
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Background
Vitamin B12 is an essential nutrient which has an im-
portant role in many processes in the body, including
DNA synthesis and DNA methylation, synthesis of blood
cells, and nerve function. Metabolically, vitamin B12 is
closely associated with folate in the regulation of key ele-
ments involving the transfer of one-carbon units [1].
Animal products like meat, poultry, fish, eggs, and milk
are the exclusive dietary sources for vitamin B12 in hu-
man nutrition [2]. The uptake of vitamin B12 in the
body is rather complex, and both salivary production of
certain B12-binding proteins, intrinsic factor in the
stomach, gastric acid, and pancreatic enzymes play a role
in absorption which ultimately takes places in the ileum
[3]. Deficiency may occur either when the food does not
contain sufficient animal products or when there is
interference in the uptake and absorptive mechanisms,
although several other factors, including exposure to ni-
trous oxide, may be involved [1, 4–6].
Excess intake of vitamin B12 or treatment of vitamin
B12 deficiency with intramuscular injections has been
considered safe for over half a century, as the compound
is water-soluble. Any excess of an injected dose will be
excreted in the urine, and the ability to absorb excessive
quantities of orally administered B12 is limited by the
restricted capacity of the receptors in the ileum [1].
Nevertheless, there have been several reports on the as-
sociation between serum B12 concentrations and in-
creased risk of disease, i.e., risk of lung cancer [7], or
even mortality. Although most epidemiologic studies
showed no association between serum B12 and cardio-
vascular disease [8–12], a recent paper suggested that
higher serum B12 concentrations were associated with
increased risk of mortality [13]. However, it should be
noted that a causal relationship between serum B12 con-
centrations and subsequent disease or mortality has
never been demonstrated. Increased serum B12 concen-
trations may be a proxy for increased intake of red meat,
inflammation due to other chronic diseases, or intake of
supplements as a complementary therapy for other con-
ditions. One very recent paper using data from the
Women’s Health Initiative (WHI) study in postmeno-
pausal women showed no association between vitamin
B12 (supplement) intake and risk of lung cancer [14].
The National Health and Nutrition Examination Sur-
vey (NHANES), a long-term epidemiologic survey in the
USA [15], has been the source for several papers on B12
and related disorders. Serum B12 concentrations have
been measured in several NHANES surveys. Recently,
we demonstrated in NHANES that serum methylmalo-
nic acid (MMA) was more strongly associated with im-
pairments of cognitive and physical functioning than
serum B12 concentration [16]. Because of the high-level
survey quality and the availability of mortality data, we
aimed to evaluate in NHANES the association between
serum B12 concentrations as well as vitamin B12 supple-
ment intake and all-cause, cardiovascular, and cancer-
related mortality. In the analyses, we adjusted for signifi-
cant demographic and lifestyle factors and comorbidities
which are known to be associated with poorer outcomes.
Methods
NHANES structure and inclusions
NHANES is a cross-sectional survey in the USA that
uses a complex, stratified, multistage probability sam-
pling design [15, 17]. The survey protocol was approved
by the Research Ethics Review Board of the National
Center for Health Statistics, and NHANES has obtained
written informed consent from all participants. For this
analysis, we used publicly available data without personal
identifiable information, and all methods were carried
out in accordance with relevant guidelines and regula-
tions. Interview questionnaires and examination re-
sponse rates are publicly available [18]. Participants were
first interviewed in their homes, during which demo-
graphic information and a variety of health-related infor-
mation were collected. One to 2 weeks later, subjects
underwent a standardized physical examination, as well
as additional investigations like exercise testing, 24-h
dietary recall, and a blood draw in a mobile examination
center. Blood samples were taken with the participant
fasting. Participants who visited the examination in the
morning were requested to fast for 9 h, those visiting in
the afternoon or evening were requested to fast for 6 h.
For this study, we included all adults aged 18 years or
older who participated in the continuous NHANES sur-
vey cycles of 1999–2000 through 2013–2014, in whom
serum B12 concentrations were assessed at baseline
(Additional file 1: Fig. 1). A total of 82,091 people partic-
ipated in the 1999–2000 through 2013–2014 NHANES
surveys. Of those, 47,279 participants were eligible for
mortality follow-up. We excluded 974 women who re-
ported to be pregnant or breastfeeding. Serum B12 was
measured in 6 of the 8 2-year surveys and available in
24,262 non-pregnant participants (51.3%).
Measurements
NHANES blood samples were processed, stored, and
shipped to the Collaborative Laboratory Services,
Ottumwa, IA. For the 1999 through 2006 surveys, serum
B12 and folate concentrations (n = 14,194) were measured
by using the Bio-Rad Laboratories “Quantaphase II
Folate/vitamin B12” radioassay kit (Bio-Rad Laboratories,
1993). In 2011–2014, serum B12 (n = 10,068) was mea-
sured using the fully automated Roche electrochemilumi-
nescence immunoassay on a Modular Analytics E170®
system (Roche Diagnostics, Indianapolis, IN). The two
methods have similar precision (< 5% CV) and limits of
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detection (LOD): 20 pg/ml for the Bio-Rad assay and 30
pg/ml for the Roche assay. Because Deming regression
considered errors in both variables, we converted all
concentrations to the BioRad values, with the proposed
equation serum B12 Bio-Rad in pg/ml = 10^(1.03 × log10(-
Roche vitamin B12) − 0.14). This re-calculation was also
based on the literature evaluating several serum B12 as-
says, in which the Elecsys system yielded results signifi-
cantly higher than the international standard [19]. In the
2013–2014 survey, NHANES quality control showed sig-
nificant shifts associated with reagent lot-to-lot variations
and adjusted the serum B12 measurements using mean
quality control pool data using a Deming regression [20].
In the 2011–2014 surveys, separate folate forms were
measured with isotope-dilution high-performance liquid
chromatography coupled to tandem mass spectrometry
(LC-MS/MS), and serum total folate was calculated by the
addition of the separate folate forms. The folate values of
the 1999–2006 surveys were re-calculated according to
NHANES instructions. Serum creatinine was measured
with the Jaffé rate method (kinetic alkaline picrate) on a
Beckman Synchron DxC800 modular chemistry analyzer.
Renal function was calculated as an estimated glomerular
filtration rate (eGFR) with the formula developed by the
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) [21]. Hemoglobin measurements and white
Fig. 1 Unadjusted all-cause mortality in NHANES 1999–2014 according to serum B12 concentrations
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blood cell count (WBC) were performed with a Beckman
Coulter MAXM between 1999 and 2012 and the Beckman
Coulter DxH 800 in 2013–2014 (Beckman Coulter Inc.,
Brea, CA, USA). No significant trend changes for
hemoglobin was reported from NHANES 1999–2012 to
NHANES 2013–2014, but there was a small change in
weighted mean WBC, from 7.03 × 103 cells/μl in 2011–
2012 to 7.41 × 103cells/μl in 2013–2014. As we used WBC
only as a covariate in our regression models, we judged
that this small change did not warrant recalculation of the
results. C-reactive protein was measured with latex-
enhanced nephelometry on a Behring nephelometer
(1999–2010), serum cholesterol was measured with an en-
zymatic method on a Hitachi 704 Analyzer (Roche Diag-
nostics), plasma glucose with a hexokinase method on a
Cobas Mira system, and HbA1c with HPLC methodology
(1999–2004 Primus CLC330 and Primus CLC 385 (Pri-
mus Corporation, Kansas City, MO), 2005–2006 on a
Tosoh A1c 2.2 Plus Glycohemoglobin Analyzer, from
2007 onwards A1c G7/G8 HPLC Glycohemoglobin
Analyzer (both Tosoh Medics, Inc., San Francisco, Ca).
Plasma total homocysteine (HCys) was measured in
1999–2006 by using a fluorescence polarization immuno-
assay (Abbott Laboratories) [22]. Serum MMA concentra-
tions were analyzed by GC/MS (1999–2004) and LC-MS/
MS (2011–2014). Both methods had an excellent correl-
ation and no bias [23]. All information regarding these
methods is publicly available on the NHANES website
[17, 24].
Medication use was scored in NHANES by the unique
generic drug code from Multum’s Lexicon Drug Data-
base. The number of different medications reported by a
participant was considered as a proxy for comorbidity
[25]. The NHANES Dietary Supplements section pro-
vides personal interview data on the use of vitamins,
minerals, and other dietary supplements. In the surveys
1999 through 2006, daily vitamin B12 intake was calcu-
lated by combining the daily dose of any supplement
with its use per month. For all supplements, reference
concentrations are given in the Dietary Supplement
Database. From these, we calculated the average daily in-
take of vitamin B12 as a supplement. Some participants
did not report frequency or dosing information or re-
ported fewer than seven dosings per month. In these, we
considered the daily vitamin B12 supplement intake as
unreliable, and therefore, it was set as “missing.” In the
surveys 2007 through 2014, total supplement intake has
already been reported for a number of vitamins and
minerals, including vitamin B12, in the total dietary sup-
plements tables.
Outcomes
The main outcomes of our study were all-cause mortality,
cardiovascular mortality, and cancer-related mortality.
Mortality status and cause of death were determined by
NHANES-linked National Death Index public access files
through December 31, 2015.
Statistical analysis
Our study population was categorized by specific serum
B12 groups: (1) group with low serum B12 concentra-
tions, defined as a serum B12 concentration < 140 pmol/
l; (2) “possible deficiency,” serum B12 concentrations be-
tween 140 and 300 pmol/l; (3) normal concentrations,
serum B12 between 300 and 700 pmol/l; and (4) elevated
serum B12 concentrations > 700 pmol/l. Daily oral intake
of vitamin B12-containing supplements was categorized
as (1) no supplement intake, (2) 0.1–4.9 mcg, (3) 5.0–
24.9 mcg, (4) 25.0–99 mcg, (5) 100–999 mcg, and (6) ≥
1000 mcg intake.
The association of serum B12 concentrations and vita-
min B12 supplement intake with all-cause mortality, car-
diovascular mortality, and cancer mortality was assessed
with Cox proportional hazards (PH) analysis. The group
with serum B12 between 300 and 700 pmol/l was set as
the reference group. The confounders which were used
in the models, were demographic factors, socioeconomic
and lifestyle factors, and relevant comorbidities and la-
boratory measurements (for details see Additional file 2,
Table 1). We plotted cumulative Kaplan-Meier curves
for mortality during follow-up according to the prede-
fined groups of serum B12 concentrations with the Stata
STKAP module [26]. Cox PH regressions were used to
estimate hazard ratios (HRs) and 95% CI for associations
between serum B12 and mortality. We built four models
to provide statistical inference. Model 1 only comprised
serum B12 concentrations, model 2 included demo-
graphic variables (age, gender, ethnicity), and model 3
included variables from model 2 plus socioeconomic and
lifestyle variables. Finally, model 4 adjusted for all vari-
ables (Additional file 2, Table 1), with the application of
the specific sampling weights according to the NHAN
ES’s instructions [27–29]. As a sensitivity analysis, we
recalculated the Cox PH model for all-cause mortality in
only participants of the 1999–2006 surveys (without and
with the inclusion of homocysteine concentrations and
C-reactive protein as an additional adjustment for
chronic inflammation) and separately only for those par-
ticipants in whom also serum concentrations of MMA
were available.
Continuous variables are presented as mean ± standard
deviation, median, and interquartile range (IQR), and
categorical variables are presented as percentages. A p
value < 0.05 was used as a cutoff for statistical signifi-
cance. Analyses were conducted using IBM SPSS Statis-
tics (Version 24, IBM, Armonk, NY, USA) and Stata
Statistical Software (version 16.0; Stata Corp, College
Station, TX, USA).
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Table 1 Baseline characteristics of participants who were still alive vs those who were deceased by December 31, 2015
Still alive, N = 21,239 Deceased, N = 3023 p value
Gender, M/F (n) 24,262 10,449/10,790 1712/1311 2.0 × 10−14
Age 18–39 years (%) 24,262 41.7 6.0 < 1.0 × 10−200
Age 40–59 years (%) 32.9 14.3
Age ≥ 60 years (%) 25.4 79.7
Body mass index (kg/m2) 23,920 28.6 ± 6.7 28.0 ± 6.2 8.8 × 10−7
Waist circumference (cm) 23,245 97 ± 16 100 ± 15 2.0 × 10−18
SBP (mmHg) 23,298 123 ± 18 138 ± 25 < 1.0 × 10−200
DBP (mmHg) 23,118 71 ± 11 69 ± 13 2.4 × 10−17
WBC (× 109/l) 24,235 7.2 ± 2.2 7.4 ± 3.3 2.1 × 10−10
Hemoglobin (mg/dl) 24,235 14.2 ± 1.5 14.0 ± 1.7 1.5 × 10−15
C-reactive protein (mg/dl) 14,174 0.19 (0.07–0.44) 0.29 (0.14–0.67) 3.9 × 10−70
Cholesterol (mmol/l) 24,138 5.0 ± 1.1 5.1 ± 1.2 2.5 × 10−7
Glucose (mmol/l) 24,141 5.5 ± 2.0 6.2 ± 2.8 1.8 × 10−63
HbA1c (%) 24,225 5.6 ± 1.0 6.0 ± 1.3 9.7 × 10−77
Creatinine (μmol/l) 24,141 72 (62–88) 80 (71–106) 8.7 × 10−80
eGFR (ml/min/1.73 m2) 24,141 100 (84–116) 77 (56–94) < 1.0 × 10−200
Serum B12 (pmol/l) 24,262 343 (257–463) 354 (252–494) 0.016
Serum folate (nmol/l) 24,182 38.7 (27.4–53.4) 37.7 (32.7–69.9) 8.4 × 10−89
Methylmalonic acid (nmol/l)1 19,492 130 (100–172) 175 (126–252) 4.9 × 10−158
Homocysteine (μmol/l)2 13,681 7.7 (6.4–9.3) 10.4 (8.3–13.3) < 1.0 × 10−200
Ethnicity 24,262 3.5 × 10−71
Mexican American (n) 3927 568
Other Hispanic (n) 1433 90
Non-Hispanic White (n) 9077 1730
Non-Hispanic Black (n) 4811 543
Others, including multi-racial (n) 1991 92
Education 22,730 1.8 × 10−166
Level 1 (%) 10.4 25.2
Level 2 (%) 14.4 19.7
Level 3 (%) 22.9 23.4
Level 4 (%) 29.5 20.2
Level 5 (%) 22.8 11.5
Annual family income 22,348 1.9 × 10−110
< 25k (%) 36.3 56.0
25–75k (%) 41.3 36.5
> 75k (%) 22.4 7.5
Never smoking (%) 23,179 51.7 39.9 3.0 × 10−33
Former smoking (%) 24,262 19.4 35.5 7.8 × 10−90
Current smoking (%) 24,262 26.5 24.0 0.003
Diabetes diagnosis (%) 24,262 14.1 29.0 1.0 × 10−97
Hypertension diagnosis (%) 24,262 30.6 60.3 2.4 × 10−226
Lipid diagnosis (%) 24,262 29.0 40.3 9.5 × 10−37
CVD diagnosis (%) 24,262 7.4 33.3 < 1.0 × 10−300
Cancer diagnosis (%) 24,262 6.5 19.4 3.3 × 10−130
Lung diagnosis (%) 24,262 11.0 16.5 4.8 × 10−19
Data are presented as mean ± SD, median (IQR), numbers or percentages
1In n = 19,492
2In n = 13,681
Wolffenbuttel et al. BMC Medicine          (2020) 18:307 Page 5 of 14
Results
Baseline characteristics
The final study population had a mean age of 48 (SD 19)
years; 50.1% were males. The median follow-up duration
was 109 months (range 1–201 months). At the census
day of December 31, 2015, 3023 participants were deter-
mined as deceased (12.5%). Reported causes of death are
summarized in Additional file 3: Table 2. Participants
who had died were older, more frequently males, had
higher blood pressure, and more frequently abnormal la-
boratory values, with higher mean concentrations of
serum creatinine (and lower eGFR), C-reactive protein,
and homocysteine, indicating a higher degree of low-
grade inflammation (Table 1). In addition, they were
more frequently former smokers, and had a higher
prevalence of diabetes, hypertension, CVD, cancer, or
lung disease. There was no difference in serum B12 con-
centrations between participants who died and those
who remained alive. Table 2 shows the relevant baseline
variables according to serum B12 concentration. As ex-
pected, lower serum B12 coincided with higher serum
MMA and homocysteine concentrations. In contrast, we
observed higher serum folate concentrations in the par-
ticipants with the highest serum B12 concentrations. For
prevalent diagnosis of diabetes, hypertension, CVD, can-
cer, and lung disease, there was a significant U-shaped
relationship, with the highest disease prevalence in the
participants with serum B12 < 140 and > 700 pmol/l.
Trends over time 1999–2014
For some variables, there was a relevant change over
time with subsequent NHANES surveys. Current
Table 2 Relevant baseline variables according to the serum B12 group
Serum B12 level (pmol/l) p value
< 140 140–300 300–700 > 700
M/F 284/310 4442/4092 6827/6639 608/1060
% females 52.2 47.9 49.3 63.5 9.0 × 10−25
Age 18–39 years (%) 23.1 38.2 39.2 21.1 1.0 × 10−71
Age 40–59 years (%) 30.3 31.3 30.0 31.3
Age ≥ 60 years (%) 46.6 30.5 30.8 47.6
Body mass index (kg/m2) 28.8 ± 6.8 29.1 ± 7.0 28.2 ± 6.5 27.9 ± 6.3 4.7 × 10−23
Waist circumference (cm) 100 ± 16 99 ± 16 96 ± 16 96 ± 15 1.2 × 10−37
SBP (mmHg) 128 ± 20 125 ± 19 124 ± 19 127 ± 21 1.0 × 10−12
DBP (mmHg) 70 ± 11 71 ± 12 70 ± 12 70 ± 12 1.1 × 10−4
C-reactive protein (mg/dl) 0.20 (0.09–0.44) 0.21 (0.08–0.50) 0.20 (0.08–0.47) 0.24 (0.09–0.56) 0.006
Serum folate (nmol/l) 34.1 (24.2–46.0) 34.3 (24.7–46.8) 41.9 (30.0–58.0) 55.1 (37.1–77.8) 3.0 × 10−209
Methylmalonic acid (nmol/l)1 272 (172–522) 150 (112–207) 124 (98–162) 122 (94–160) 3.8 × 10−194
Homocysteine (μmol/l)2 13.0 (9.5–18.3) 8.7 (7.1–11.0) 7.7 (6.4–9.4) 7.3 (5.8–9.1) 8.8 × 10−109
Annual family income 0.035
< 25k (%) 43.8 39.6 37.9 38.1
25–75k (%) 39.1 40.1 41.2 40.8
> 75k (%) 17.1 20.3 20.9 21.1
Never smoking (%) 51.1 47.0 51.3 56.9 8.7 × 10−15
Former smoking (%) 21.5 20.9 21.3 25.4 0.001
Current smoking (%) 26.4 30.0 24.9 16.7 9.3 × 10−33
Use of vitamin B12-containing supplements (%) 17.0 20.3 35.2 59.5 2.6 × 10−264
Diabetes diagnosis (%) 21.9 15.2 15.3 22.8 8.6 × 10−18
Hypertension diagnosis (%) 43.1 34.3 32.6 45.4 4.3 × 10−28
Lipid diagnosis (%) 32.8 29.9 29.7 37.0 1.3 × 10−8
CVD diagnosis (%) 16.5 10.4 9.9 15.0 2.0 × 10−13
Cancer diagnosis (%) 10.1 7.6 7.9 11.5 4.8 × 10−7
Lung diagnosis (%) 14.5 11.7 11.3 13.9 0.002
Data are presented as mean ± SD, median (IQR), numbers, or percentages
1In n = 19,492
2In n = 13,681
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smoking remained rather stable between 1999 and 2000
and 2013–2014, amounting 19.5 and 20.4% of partici-
pants, respectively (p = 0.137), although there was a
gradual decrease in the percentage of former smokers
(25.9–26.9% between 1999 and 2000 and 2003–2004 vs
23.1% in 2011–2012 and 2013–2014, p < 0.001). The
mean BMI increased from 28.3 ± 6.3 kg/m2 in 1999–
2002 to 29.0 ± 7.0 kg/m2 in 2011–2014. There was a sig-
nificant increase in the percentage of participants with a
diagnosis of diabetes (11.8% in 1999–2000, 19.4% in
2013–2014, p < 0.001), hypertension (34.7% vs 39.6%,
p < 0.0001), cancer (6.3% vs 9.2%, p < 0.001), and lung
disease (7.5% vs 13.3%, p < 0.001). Also, we observed a
significant increase in the use of high-dose vitamin B12-
containing supplements: in the surveys of 1999–2002,
2.7–3.3% were taking supplements containing ≥ 100 mcg
cobalamin and 0.1–0.2% ≥ 1000 mcg. In the surveys
2011–2012 and 2013–2014, this had increased to 5.9–
6.7% and 2.9–3.1%, respectively.
Association with mortality
The association of serum B12 concentrations with mor-
tality was U-shaped, with significantly higher mortality
with low as well as with high serum B12 (Fig. 1, Add-
itional file 4: Table 3). The Kaplan-Meier analysis re-
vealed statistically significant (p < 0.001, Fig. 2, top)
differences in survival probabilities across the four serum
B12 groups. The unadjusted analysis indicated the lowest
survival in participants with serum B12 < 140 pmol/l and
> 700 pmol/l. After adjustment for all relevant con-
founders (Fig. 2, bottom), only the survival curve for par-
ticipants with serum B12 < 140 pmol/l deviated from the
3 other curves. These observations are confirmed by the
detailed Cox proportional hazard analyses (Fig. 3). In un-
adjusted analyses, both low and high serum B12 concen-
trations were associated with a higher odds ratio of all-
cause and cardiovascular mortality. The adjusted ana-
lyses indicated that low serum B12 < 140 pmol/l
remained significantly associated with all-cause and car-
diovascular mortality, while high serum B12 > 700 pmol/
l was associated with increased cardiovascular mortality
only. In none of the adjusted models could we demon-
strate a relationship between serum B12 concentrations
and cancer-related mortality.
Vitamin B12-containing supplements
In total, 7877 participants reported the use of oral vita-
min B12-containing supplements in any form. Users of
these supplements more frequently had a diagnosis of
hypertension (35.7 vs 28.8%), hyperlipidemia (35.6 vs
29.2%), CVD (34.1 vs 30.8%), and cancer (44.8 vs 29.9%,
all p < 0.001). A higher intake of vitamin B12 by supple-
ments coincides with higher serum B12 concentrations
(Table 3). Nevertheless, all groups contain participants
with markedly elevated serum B12 concentrations. Al-
though the unadjusted Cox proportional hazards analysis
suggested a difference in all-cause mortality between dif-
ferent supplemental B12 intakes (Fig. 4), none of the ad-
justed models showed increased mortality in relation to
intake of vitamin B12-containing supplements.
Sensitivity analyses
The hazard ratio of low serum B12 for both all-cause
and cardiovascular mortality in the fully adjusted model
is similar in the 1999–2006 participants compared to the
entire cohort (Additional file 5: Table 4). However, it is
no longer significant when adjusted additionally for the
powerful biomarkers homocysteine and MMA which in-
crease when there is symptomatic or functional vitamin
B12 deficiency. The association between high serum B12
and all-cause mortality has a comparable hazard ratio
for all sensitivity analyses.
Discussion
Our unadjusted data showed a U-shaped association be-
tween serum B12 concentrations and subsequent all-
cause mortality after a median follow-up duration of
109 months in NHANES participants aged 18 and above.
After adjusting for relevant confounders, including so-
cioeconomic status, education, ethnicity, smoking, co-
morbidity, and laboratory parameters, low serum B12
was associated with a moderate increase in all-cause and
Table 3 Distribution of the use of oral vitamin B12-containing supplements and concomitant serum B12 concentrations
Vitamin B12
supplements
Number Serum B12 (pmol/l) Serum
B12 < 140
Serum
B12 > 1000Median (IQR) Minimum Maximum
No supplements 16,385 321 (242–423) 10.5 148,936 488 (3.0%) 211 (1.3%)
0–4.9 mcg 1115 345 (258–458) 75.3 9810 22 (2.0%) 19 (1.7%)
5–24.9 mcg 3358 391 (294–523) 25.1 75,645 47 (1.4%) 83 (2.5%)
25–99 mcg 1774 428 (321–564) 36.9 4794 24 (1.4) 61 (3.4%)
100–999 mcg 780 502 (373–696) 86.4 7557 4 (0.5%) 80 (10.3%)
> 1000 mcg 387 732 (495–1198) 103 8576 3 (0.8%) 125 (32.3%)
Unknown 463 377 (280–548) 34.7 33,837 6 (1.3%) 26 (5.6%)
Participants reporting the use of B12 injections under dietary supplements or prescription medications were excluded
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cardiovascular mortality. Sensitivity analyses revealed
that this effect was no longer significant when adjusted
for the relevant biomarkers homocysteine and MMA,
which indicate a tissue B12 deficiency. High serum B12
concentrations > 700 pmol/l were associated with an in-
crease in cardiovascular mortality only (HR 1.45, 95% CI
1.01–2.06, p = 0.042). Participants with a diagnosis of
hypertension, dyslipidemia, CVD, and cancer more fre-
quently used vitamin B12-containing supplements than
those without these diagnoses. Congruently, we found
no indication that a higher intake of vitamin B12-
containing supplements was associated with adverse ef-
fects on mortality.
Traditionally, it was believed that the principal and in-
evitable consequence of vitamin B12 deficiency was
megaloblastic anemia as part of a well-characterized syn-
drome that was described decades ago. Current evi-
dence, however, suggests that frequently hematological
manifestations are entirely absent [1, 4]. There is only
limited information on the long-term consequences of
low serum B12 concentrations. A study in Finland
showed an association between the lowest tertile of
serum B12 concentrations and the risk of mortality due
to vascular events or dementia [30]. A Dutch study
could not confirm this, but these observations comprised
only a small group of patients after myocardial infarc-
tion, and serum B12 concentrations were measured soon
after the event [31]. A review by Rafnsson concluded
that there was limited evidence that vitamin B12 defi-
ciency predisposes to the risk of mortality and morbidity
Fig. 2 Kaplan-Meier survival estimates for the serum B12 groups, unadjusted (top) and fully adjusted for covariates (bottom)
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from either cardiovascular diseases or diabetes in adults
[32]. Data from the LURIC study, however, showed a
similar U-shaped curve for the association between
serum B12 and mortality as in the present study [33].
These authors proposed that in low serum B12, mortal-
ity—and the accompanying accelerated telomere short-
ening—might be driven by increased concentrations of
homocysteine, while in participants with high serum
B12, this might be related to increased inflammation.
Since the advent of mandatory fortification of the food
supply with folic acid in the USA in 1998, vitamin B12
deficiency has become the leading modifiable cause of
elevated homocysteine levels in the population [34].
These results are confirmed by our sensitivity analyses,
in which the hazard ratio of low serum B12 for both all-
cause and cardiovascular mortality is no longer signifi-
cant when adjusted additionally for homocysteine
concentrations.
The (epidemiologic) relationship of increased serum
B12 concentrations and subsequent disease or mortality
Fig. 3 Cox proportional hazards analysis for all-cause, cardiovascular, and cancer-related mortality according to serum B12 concentrations in 19,034 participants
of the NHANES surveys 1999–2014 with complete data. Data show hazard ratio and 95% CI, for 4 models. Panel 1, unadjusted. Panel 2, adjusted for age
(categorical, < 40, 40–60, > 60), gender, and ethnicity. Panel 3, adjusted for age, gender, ethnicity, BMI group (categorical, < 20, 20–25, 25–30, 30–35, 35–40, >
40), family income (categorical, < $25,000, $25000–75,000, > $75,000), education level, former and current smoking, and alcohol consumption. Panel 4, adjusted
for age; gender; ethnicity; BMI group; family income; education level; former and current smoking; alcohol consumption; eGFR < 60ml/min/1.73m2; diagnosis
of diabetes, hypertension, cardiovascular disease, cancer, and lung disease; medication use (as a proxy for other comorbidities); white blood cell count;
hemoglobin; and serum folate
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has been the topic of several papers (Additional file 6:
Table 5), showing the putative prognostic significance of
increased serum B12 concentrations in people who were
acutely ill. Several studies reported that high serum B12
concentrations predicted mortality in alcoholic hepatitis
[35], inpatients [36–40], and in those critically ill [41]. In
contrast, in patients with ischemic stroke, low serum
B12 was associated with lower Glasgow Coma Scale
scores and higher mortality [42]. Elevated serum B12
was associated with severity of disease in acute-on-
chronic liver failure [43], interstitial renal disease, liver
cirrhosis, hepatitis, and liver metastases [44] and proved
to be a marker of poor liver function, but not a predictor
of mortality after admission to an intensive care unit
[45]. These data altogether suggest that serum B12 con-
centrations increase as a consequence of acute and
chronic illness. Several hypotheses have been postulated
regarding the mechanism behind this, including an up-
regulation of haptocorrin synthesis, an increased release
of cellular cobalamin, for instance in liver disorders
Fig. 4 Association between the use of oral vitamin B12 supplement intake (in mcg per day) and hazard ratio for all-cause, cardiovascular, and
cancer-related mortality in 18,666 participants of the NHANES surveys 1999–2014 with complete data. Panel 1, unadjusted. Panel 2, adjusted for
age (categorical, < 40, 40–60, > 60), gender, and ethnicity. Panel 3, adjusted for age, gender, ethnicity, BMI group (categorical, < 20, 20–25, 25–30,
30–35, 35–40, > 40), family income (categorical, < $25,000, $25,000–75,000, > $75,000), education level, former and current smoking, and alcohol
consumption. Panel 4, adjusted for age; gender; ethnicity; BMI group; family income; education level; former and current smoking; alcohol
consumption; eGFR < 60 ml/min/1.73 m2; diagnosis of diabetes, hypertension, cardiovascular disease, cancer, and lung disease; medication use (as
a proxy for other comorbidities); white blood cell count; hemoglobin; and serum folate
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during hepatic cytolysis, or a reduction of cobalamin
clearance by a diseased liver [46]. The associations that
have been reported by others between high serum B12
concentrations and morbidity or mortality and the pro-
posed underlying mechanism of such associations are
plausible, invoking, as they do, a primary disease process
that leads to secondary elevation of circulating B12 con-
centrations, presumably through tissue release of vitamin
B12. However, there is nothing in those reports that in-
dicates causality in the direction of a priori raised serum
B12 leading to increased mortality. While the findings in
our study confirm the overall U-shaped association of
serum B12 concentration with mortality, they lend no
support to the suggestion that high serum B12 concen-
trations per se are harmful or detrimental.
Studies in people who were not acutely ill showed
varying results. Most authors reported no association be-
tween serum B12 and cardiovascular disease or death
due to coronary heart disease [8–12], one study reported
inconsistent results [47], while some reported increased
all-cause mortality with higher serum B12 [13, 48, 49].
The reports in cancer are even more confusing. In one
study, higher serum B12 indicated increased prostate
cancer risk [50], but this was not confirmed in another
study [51]. Higher serum B12 predicted lower overall
survival in patients with metastatic cancer [52]. Plasma
folate and B12 concentrations were not associated with
breast cancer risk in women recruited to the Varese
(Italy) cohort of the European Prospective Investigation
into Cancer and Nutrition (EPIC) study, while high
plasma vitamin B6 was associated with lower risk [53].
Serum B12 concentrations were not associated with lung
cancer risk in a large meta-analysis [54]. In contrast, a
recent paper suggested that increasing serum B12 con-
centrations were associated with an increased risk for
lung cancer [7]. A doubling of B12 concentrations was
calculated to be associated with a 15% increase of risk.
The increased risk was not observed in participants who
never smoked. Interestingly, the reported increased risk
for lung adenocarcinoma was associated with the specific
effect of specific single nucleotide polymorphisms
(SNPs), which increase circulating serum B12 [7]. One
of these is a SNP in the gene fucosyltransferase 2
(FUT2), where the FUT2 non-secretor rs601338(AA)
variant is associated with a 10–25% higher total and
haptocorrin-bound B12, but not transcobalamin-bound
B12 [55].
Our current paper could not demonstrate any relation-
ship between dietary vitamin B12 intake and cancer
mortality. In previous reports, dietary intake of vitamin
B12 (as well as folate and B6) or B12 supplement use
was not associated with increased risk of renal [56],
nasopharyngeal [57], or lung cancer [14] and was associ-
ated with a lower risk of pancreatic cancer [58] and
decreased risk of breast cancer in BRCA mutation car-
riers [59]. In the Women’s Antioxidant and Folic Acid
Cardiovascular Study, intervention with a combination
of folic acid (2.5 mg daily), vitamin B6 (50 mg), and
cyanocobalamin (1000 mcg) for 7.3 years had no effect
on the overall risk of cancer or cancer mortality [60]. In
contrast, the combined analysis of two studies in
Norway—where there is no folic acid fortification of
foods—showed that treatment of patients with ischemic
heart disease using folic acid (0.8 mg) plus cyanocobala-
min (400 mcg) was associated with increased cancer risk
and all-cause mortality. The authors suggest that these
adverse effects were mediated by folic acid [61]. Supple-
mentation with folate, vitamins B6 and B12, and/or
omega-3 fatty acids in a secondary prevention trial
showed no benefit of low doses of vitamin B6 (3 mg),
cyanocobalamin (20 mcg), and 5-methyltetrahydrofolate
(0.56 mg) on cancer incidence or cancer mortality in pa-
tients with cardiovascular disease [62].
An important question, which cannot be answered
with the current dataset, is whether and why many
NHANES participants might have taken extra vitamin
B12-containing supplements. Several participants took
high doses of vitamin B12, in the range of 100 to
6000 mcg per day, while the recommended daily allow-
ance (RDA) for adults is 2.4 mcg/day. For some, this
might have been a treatment of demonstrated vitamin
B12 deficiency or additional nutrient supplementation in
the case of vegetarians, for others, such supplement use
was either self-driven or by the recommendation of a
health care provider. We clearly showed that the use of
vitamin B12-containing supplements has increased dur-
ing the more recent NHANES surveys and was signifi-
cantly higher in participants with hypertension,
dyslipidemia, CVD, and an earlier diagnosis of cancer.
The association between elevated serum B12 and cardio-
vascular mortality, together with the absence of any as-
sociation between high B12 supplement intake and
mortality likely indicates “reverse causality.” The in-
creased use of vitamin B12-containing supplements by
people with a chronic (cardiovascular) condition sup-
ports this conclusion, as well as the growing body of lit-
erature that serum B12 concentrations increase in states
of inflammation [33]. However, there are several other
factors which by themselves may negatively influence
long-term morbidity and mortality, and are associated
with higher serum B12 concentrations, for instance, high
consumption of red meat. A higher intake of processed
meat and unprocessed red meat may be associated with
a small increased risk of incident CVD and all-cause
mortality [63–65]. In the dataset, we observed several in-
dividuals with markedly elevated serum B12 concentra-
tions which were not explained by oral supplement use
or registered cobalamin-containing prescription
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medication. This could suggest “hidden” or non-
reported use of such preparations or injectable use of
vitamin B12 (personal communication prof. R.K. Bailey),
but it may also indicate other factors which may lead to
artificially elevated serum B12 concentrations such as re-
cent infection, or the existence of circulating B12 im-
mune complexes [66, 67].
Our sensitivity analyses confirm the robustness of our
findings. The hazard ratio of low serum B12 for both all-
cause and cardiovascular mortality is similar in a subset of
participants, i.e., those included between 1999 and 2006,
but is no longer significant when adjusted additionally for
homocysteine or MMA concentrations. Both have been
considered biomarkers with high sensitivity, and in the
case of MMA, also specificity, indicating B12 deficiency at
the tissue level [68], although several authors have re-
ported normal MMA values even with severely low serum
B12 concentrations [5, 69–71]. Previously, we have shown
in NHANES 2011–2014 participants that serum MMA
concentrations were a more reliable predictor of com-
plaints, functional status, and physical performance than
serum B12 [16]. This may also explain why the association
between serum B12 and mortality loses its significance
when adjusted for MMA concentrations. The observed as-
sociation between high serum B12 and cardiovascular
mortality has a comparable hazard ratio of 1.41–1.46 for
all sensitivity analyses but lost its significance due to a
lower number of participants with complete data evalu-
ated in the 1999–2006 surveys (Additional file 5: Table 4).
Prospective follow-up studies do have pitfalls. Diet-
ary habits recorded at baseline may significantly
change during the course of several years of follow-
up, especially when people develop intercurrent disor-
ders like myocardial infarction or diabetes. Also, so-
cioeconomic situations may improve or worsen, and
alterations in exercise and other environmental factors
like sleeping habits or sleep quality or medication use
may affect the development of morbidity and death.
In the current analysis in NHANES, no follow-up
data other than mortality were available. Future stud-
ies in which repeated measurements and question-
naires are taken over time may validate the reported
associations. Such studies are however very expensive
to organize and perform. Despite this, the current
analyses have tried to incorporate as far as possible
the relevant confounders for the development of mor-
bidity and mortality, including socioeconomic status,
education, ethnicity, comorbidity, and laboratory pa-
rameters, thereby showing the strength of this very
large NHANES dataset.
Conclusions
After adjustment for relevant demographic and lifestyle
factors as well as existing comorbidity, low serum B12
concentrations were independently associated with a
slight increase of all-cause and cardiovascular mortality.
Elevated serum B12 was associated with a small increase
in cardiovascular mortality only. High intake of vitamin
B12 in the form of supplements was not associated with
increased all-cause mortality, supporting its safe use.
Vitamin B12 deficiency is prevalent, particularly among
the elderly, and is associated with serious morbidity. The
diagnosis of such deficiency is often elusive so that the
use of B12 supplements has become widespread, because
of its low cost and presumed safety. Recent reports
based on associations have raised the specter that high
B12 levels may be harmful and have discouraged B12
supplement use with potentially harmful consequences.
The overall public health impact of our findings is to
provide reassurance that high B12 levels per se are not a
cause of higher mortality risk.
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